Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Genetics 52

Genetics Research Medicine Clinical Research 52

XTalks

DECEMBER 13, 2023

3) Fulgent Genetics Compound annual growth rate: 260 percent Fulgent Genetics, headquartered in California, is a technology-driven company with a strong presence in clinical diagnostics and therapeutic development. The company achieved core revenues of $67 million, reflecting a remarkable 48 perecent year-over-year growth.

Genetics 111

Genetics Vaccination Vaccine DNA 111

Drug Discovery World

JULY 29, 2022

Scientists modelling the cancer-suppressing p53 gene identify how the 20 different molecules unique to elephants get activated for increased sensitivity and response against carcinogenic conditions – with implications for cancer treatments in humans.

Gene 52

Gene DNA Protein Genetics 52

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. Such information can reveal details about tumor staging, tumor progression, heterogeneity, gene mutations and clonal evolution. Concentration of cfDNA and ctDNA in Cancer Patients.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

OCTOBER 25, 2023

There are two main concepts underlying this impact; we’ve known for a few years now that people can have variable responses to the same medication and that these responses are largely based on an individual’s genetic makeup. NGS is becoming invaluable for treating individual cancer patients based on their tumour’s genetic makeup.

Bioinformatics 115

Bioinformatics Genetics RNA Drugs 115

Drug Discovery World

NOVEMBER 15, 2022

Rapid and accurate DNA synthesis . Conventional DNA synthesis, typically used for making sequences such as primers, employs phosphoramidite chemistry, a method that was developed in the 1980s and is still considered the gold standard for DNA synthesis. .

DNA 98

DNA Drugs Antibody Engineer 98

pharmaphorum

SEPTEMBER 14, 2020

Last week geneticist Dr Charles Steward shared with us his experiences of searching for a genetic cause for his children’s rare neurological diseases. While there may be just under 20,000 confirmed protein coding genes, it turns out that much of the genome outside of these genes is also important in regulating how the genome is controlled.

Genome 119

Genome Genomics Medicine Gene 119

Drug Discovery World

JULY 26, 2023

With 100-fold the number of genes in the human genome 1 , this microbial collection is a rich genetic signature of clinical significance that we have only recently gained the tools to explore. Collectively, these systems biology bioinformatic puzzles often require partnerships to solve.

Medicine 52

Medicine Genome Genomics Bioinformatics 52

Drug Discovery World

APRIL 14, 2023

Whilst the cause of DIPG isn’t known, the disease is characterised by specific mutations in genes coding for histone proteins – a family of basic proteins which can associate with DNA due to their positive charges. BMC Bioinformatics. These mutated proteins then reprogramme the epigenome, from which the cancer develops.

Protein 52

Protein Genome Genomics DNA 52

Drug Discovery World

NOVEMBER 9, 2023

Klaus Wagenbauer, PhD, Founder & CEO, Plectonic, on: ‘Programmable DNA-origami-based T cell engagers: PTE’. Marine Houdou, Genetic Engineering Specialist, Polyplus, on: ‘From modular DNA assembly to recombinant protein production at Polyplus’. The session ends with two presentations and two luncheon presentations.

Engineer 52

Engineer Antibody Protein In-Vivo 52

The Pharma Data

JANUARY 10, 2021

I actually think neuroscience is going to heat up in 2021,” said Ben Zeskind , co-founder and CEO of Immuneering , which is using bioinformatics and computational biology to develop new drugs in this space, along with oncology and immuno-oncology. Moving on From the Amyloid Hypothesis. “I Same with Alzheimer’s.

Vaccination 52

Vaccination Vaccine Regulation Drugs 52